When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Hepatitis A

Evidence last reviewed: 22 Oct 2026
Topic last updated: 17 Sep 2026

Summary

Definition

History and exam

Key diagnostic factors

  • fever
  • malaise
  • nausea and vomiting
  • jaundice
  • hepatomegaly
  • right upper quadrant pain
  • clay-colored stools
Full details

Other diagnostic factors

  • fatigue
  • headache
  • dark urine
  • pruritus
  • arthralgias and myalgias
  • cough
  • diarrhea
  • constipation
  • splenomegaly
  • posterior cervical lymphadenopathy
  • evanescent rash
  • bradycardia
Full details

Risk factors

  • living in endemic region
  • travel to endemic region
  • close personal contact with an infected person
  • men who have sex with men
  • known foodborne outbreak
  • illegal drug use
  • homelessness
  • occupational exposure
Full details

Diagnostic tests

1st tests to order

  • serum aminotransferases
  • serum bilirubin
  • BUN
  • serum creatinine
  • prothrombin time
  • immunoglobulin M (IgM) antihepatitis A virus (HAV)
Full details

Tests to consider

  • immunoglobulin G (IgG) antihepatitis A virus (HAV)
  • hepatitis A virus RNA detection
Full details

Treatment algorithm

INITIAL

unvaccinated people with recent exposure to hepatitis A (<2 weeks)

ACUTE

confirmed hepatitis A

Contributors

Authors

Doan Y Dao, MD

Assistant Professor of Medicine

Director, Center of Excellence for Liver Disease in Vietnam

Johns Hopkins School of Medicine

Department of Medicine

Division of GI and Hepatology

Baltimore, MD

Disclosures

DYD receives grants from Roche Diagnostics International Ltd and Gilead Sciences.

Acknowledgements

Dr Doan Dao would like to gratefully acknowledge Dr Musaddiq Waheed and the late Dr Fida A. Khan, the previous contributors to this topic.

Disclosures

MW and FAK declared that they have no competing interests.

Peer reviewers

Howard J. Worman, MD

Professor of Medicine and Cell Biology

Columbia University College of Physicians and Surgeons

New York, NY

Disclosures

HJW declares that he has no competing interests.

Srikrishna Nagri, MD

Gastroenterologist

Dartmouth-Hitchcock Nashua

Nashua, NH

Declarações

SN declares that he has no competing interests.

George Y. Wu, MD, PhD

Professor of Medicine

University of Connecticut Health Center

Farmington, CT

Declarações

GYW is on the medical advisory boards of the following: Gilead Sciences, Bristol-Myers Squibb, AbbVie, and Intercept.

Kittichai Promrat, MD

Assistant Professor

Division of Gastroenterology

Department of Medicine

Brown University, RI

Declarações

KP declares that he has no competing interests.

Pierre Van Damme, MD, PhD

Professor

Director of Vaccine & Infectious Disease Institute

University of Antwerp

Antwerp

Belgium

Declarações

PVD has been and still is principal investigator of vaccine trials for several vaccine manufacturing companies, from which the university obtained and obtains research contracts and funds for conducting such vaccine trials.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

​Centers for Disease Control and Prevention. Hepatitis A. [internet publication].Texto completo

Kemmer NM, Miskovsky EP. Hepatitis A. Infect Dis Clin North Am. 2000 Sep;14(3):605-15. Resumo

Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1-38.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Hepatitis A images
  • Diagnósticos diferenciais

    • Acute hepatitis B
    • Hepatitis E
    • Acute hepatitis C
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2025​
    • Child and adolescent immunization schedule by age: recommendations for ages 18 years or younger, United States, 2025
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal